#United States #New York #Class Action #Lead Plaintiff #Actinium Pharmaceuticals

Urgent Reminder for Actinium Pharmaceuticals Shareholders

In a recent announcement, The Gross Law Firm has issued an alert to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM), reminding them of an impending deadline for potential participation in a class action lawsuit. Shareholders who acquired shares within the specified class period are strongly encouraged to reach out to the firm regarding the possibility of being appointed as a lead plaintiff. However, it is crucial to note that being designated as a lead plaintiff is not a prerequisite for obtaining any potential recovery from the case.

Class Period Details

The class period identified for this lawsuit spans from October 31, 2022, to August 2, 2024. During this timeframe, various allegations have arisen against the company, claiming that it issued materially false and misleading statements. Furthermore, there were failures to disclose critical information that investors deemed significant.

Allegations Against Actinium Pharmaceuticals

The legal complaint outlines several allegations against Actinium Pharmaceuticals, stating that:
1. The data from the Phase 3 Sierra trial was unlikely to meet the FDA's requirements for acceptance and approval of the company’s targeted radiotherapy, known as Iomab-B.
2. Additional analyses that purportedly indicated an enhanced Overall Survival trend offered to the FDA were unlikely to satisfy their stringent approval guidelines.
3. Due to these reasons, there was a strong possibility that the FDA would refuse to review or approve the Iomab-B BLA in its current form.
4. Consequently, the defendants' optimistic assertions regarding the company’s operations and future prospects were deemed materially misleading and lacking a reasonable basis.

Key Deadline for Shareholders

As highlighted in the announcement, shareholders must take action to register for this class action by the deadline of May 27, 2025. Delayed registration could affect their ability to participate in the case. The Gross Law Firm emphasizes that registration is simple and entails no costs or obligations for the shareholder.

What Happens Next?

Once a shareholder registers as a participant who purchased shares of Actinium Pharmaceuticals within the specified timeframe, they will gain access to portfolio monitoring software. This tool is designed to keep them updated on the lawsuit’s progress throughout its lifecycle. The firm is dedicated to providing valuable support and information to shareholders who may have suffered losses.

Why Choose The Gross Law Firm?

The Gross Law Firm has established itself as a nationally recognized entity in handling class action lawsuits. Its primary mission is to defend the rights of investors adversely affected by deceptive business practices and fraud. The firm prioritizes accountability, ensuring companies maintain responsible corporate citizenship and adhere to ethical business standards.

For investors, the opportunity to recover losses tied to fallacious information or omissions in disclosure from Actinium Pharmaceuticals is a priority. Potential participants are encouraged to reach out and learn more about how they can get involved.

Contact Information

For further assistance or to take the necessary steps, shareholders can contact:
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY 10018
Email: [email protected]
Phone: (646) 453-8903

In conclusion, this notification serves as a potent reminder for all shareholders of Actinium Pharmaceuticals to act promptly to safeguard their interests before the critical deadline approaches. The Gross Law Firm is committed to ensuring that every investor has the opportunity to seek justice and recover losses incurred during this troubling period.